×
0 0 0.00564705882352944 -0.0117647058823528 -0.0350588235294118 -0.0343529411764706 -0.04 -0.0367058823529412
Stockreport

Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena Failed [Seeking Alpha]

VIVUS (VVUS)  More Company Research Source: Seeking Alpha
Last vivus earnings: 8/7 04:05 pm Check Earnings Report
US:NASDAQ Investor Relations: ir.vivus.com/node/5806
PDF Novo Nordisk Can Succeed In Weight Loss Where Orexigen, Vivus, Arena FailedSummaryNovo Nordisk's injectable semaglutide succeeded in Phase II trials for weight loss, and injectable liraglutide already sells near $500M annually.Oral semaglutide already succeeded in Phase III trials for the diabetes market.An oral semaglutide for the weight loss market could be big for Novo and open up the weight loss market significantly. [Read more]

IMPACT SNAPSHOT EVENT TIME: VVUS
Last Price
Price Change
Price Change %
Volume Shares
Max Up
Max Down
Volume Ratio
%
Performance comparison Updated
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
LAST PRICE
VWAP
High:
MAX UP
High:
Low:
MAX DOWN
Low:
%
POST NEWS RANGE
%
PRICE CHANGE

PRICE CHANGE PERCENTAGE


S&P 500 (SPX)

%

VOLUME RATIO
%

VOLUME (SHARES)
TICKS

AVG SHARES PER TRADE

Don't Miss Out On The Next BIG Stock Move
EVENT DAY
Event Day Chart will not be displayed beyond 90-day period of the event
PERFORMANCE SINCE EVENT
TIME AND VELOCITY ANALYSIS
Opt-in for
VVUS alerts
from News Quantified